BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics
GET POWR RATINGS... FREE!
BVXV Stock Price Chart Interactive Chart >
BVXV Price/Volume Stats
| Current price | $2.30 | 52-week high | $22.90 |
| Prev. close | $2.34 | 52-week low | $2.03 |
| Day low | $2.25 | Volume | 6,298 |
| Day high | $2.36 | Avg. volume | 193,466 |
| 50-day MA | $2.49 | Dividend yield | N/A |
| 200-day MA | $7.87 | Market Cap | 4.30M |
BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio
Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.
Latest BVXV News From Around the Web
Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.
BiondVax to Present at BIO-Europe SpringJERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring toge |
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir ReichmanLOS ANGELES, CA - (NewMediaWire) - March 06, 2023 - (InvestorBrandNetwork via NewMediaWire) - Multifaceted financial news and publishing company IBN today announces the release of the latest episode of the popular Test. The episode is hosted by Jason Fishman of Digital Niche Agency. |
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesLOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), recently appeared on the popular Test. Optimize. Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. The broadcast, hosted by Jason Fishman, SVP D |
BiondVax Presenting at BIO CEO & Investor ConferenceJERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The conference is taking place Feb. 6-9, 2023, in New York. Reichman’s presentation will focus on recent succ |
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment CandidateBiondVax Pharmaceuticals Ltd (NYSE: BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial. But the untreated control group's weight declined 12% on average, a highly statistically significant difference. The prophylactic r |
BVXV Price Returns
| 1-mo | -1.71% |
| 3-mo | -29.45% |
| 6-mo | -76.13% |
| 1-year | -82.31% |
| 3-year | -96.29% |
| 5-year | -96.25% |
| YTD | -22.30% |
| 2022 | -87.40% |
| 2021 | -16.37% |
| 2020 | -69.75% |
| 2019 | 94.76% |
| 2018 | -11.01% |
Loading social stream, please wait...